Apisa Biotech Extn Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 42.49%
(FY 2021)
- Profit 9.13%
(FY 2021)
- Ebitda 10.99%
(FY 2021)
- Net Worth 60.26%
(FY 2021)
- Total Assets 147.69%
(FY 2021)
About Apisa Biotech Extn
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rakhi Majumder and Debasish Majumdar serve as directors at the Company.
- CIN/LLPIN
U24116TG2016PTC109365
- Company No.
109365
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Apisa Biotech Extn Private Limited offer?
Apisa Biotech Extn Private Limited offers a wide range of products and services, including Fertilizers and Soil Additives, Micronutrient Fertilizers, Animal Medicines & Health Care, Veterinary Medicines.
Who are the key members and board of directors at Apisa Biotech Extn?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakhi Majumder  | Director | 03-May-2016 | Current |
| Debasish Majumdar | Director | 03-May-2016 | Current |
Financial Performance of Apisa Biotech Extn.
Apisa Biotech Extn Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 42.49% increase. The company also saw a slight improvement in profitability, with a 9.13% increase in profit. The company's net worth Soared by an impressive increase of 60.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apisa Biotech Extn?
In 2021, Apisa Biotech Extn had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Apisa Biotech Private LimitedActive 11 years 10 monthsRakhi Majumder and Debasish Majumdar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Apisa Biotech Extn?
Apisa Biotech Extn has a workforce of 16 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apisa Biotech Extn, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apisa Biotech Extn's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
